- Home
- PRME vs GOSS Comparison
PRME vs GOSS Comparison
Compare PRME & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRME | GOSS |
|---|---|---|
| Founded | 2019 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 666.1M | 796.2M |
| IPO Year | 2022 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PRME | GOSS |
|---|---|---|
| Price | $4.04 | $2.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $6.42 | ★ $8.60 |
| AVG Volume (30 Days) | 3.7M | ★ 4.7M |
| Earning Date | 02-27-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $5,977,000.00 | ★ $44,051,000.00 |
| Revenue This Year | $111.80 | N/A |
| Revenue Next Year | N/A | $6.41 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 647.13 | N/A |
| 52 Week Low | $1.11 | $0.76 |
| 52 Week High | $6.94 | $3.87 |
Technical Indicators
Market Signals| Indicator | PRME | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 58.09 | 30.53 |
| Support Level | $3.29 | $3.04 |
| Resistance Level | $4.12 | $3.87 |
| Average True Range (ATR) | 0.25 | 0.28 |
| MACD | 0.04 | -0.14 |
| Stochastic Oscillator | 86.93 | 2.40 |
Price Performance
Historical ComparisonAbout PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.